Business Context and Reporting Period
This Form 8-K Current Report from Krystal Biotech, Inc. (KRYS) covers the annual meeting of stockholders held on May 21, 2021. The company is incorporated in Delaware and trades on the Nasdaq. The filing details the results of shareholder votes regarding board elections and auditor ratification.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance events and does not contain financial performance data.
Material Changes
No material financial changes or operational updates are reported in this filing. The document serves solely to disclose the outcomes of the shareholder vote.
Guidance, Outlook, and Management Commentary
The filing contains no guidance, outlook, management commentary, risks, contingencies, or unusual items. It strictly reports the voting results for the election of directors and the ratification of the independent registered public accounting firm.
Key Facts for Investors to Verify
- Director Elections: Two Class I directors, Suma Krishnan and Julian Gangolli, were elected to the Board of Directors for terms expiring at the 2024 annual meeting.
- Voting Results: Suma Krishnan received 14,443,849 votes for, while Julian Gangolli received 14,926,119 votes for. Both had 2,571,068 broker non-votes.
- Auditor Ratification: Shareholders ratified the selection of Mayer Hoffman McCann P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2021, with 19,783,665 votes for and 8,120 votes against.
- Emerging Growth Company Status: The registrant is identified as an emerging growth company and has elected not to use the extended transition period for complying with new or revised financial accounting standards.